clinical trial · NCT05371093
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Kite, A Gilead Company·phase3·active not recruiting·n = 231
Relapsed/Refractory Follicular LymphomaAxicabtagene CiloleucelCyclophosphamideFludarabineLenalidomideRituximabDoxorubicinVincristinePrednisone
brief summary
The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma
started
Sep 22, 2022
primary completion
Oct 1, 2030
completion
Oct 1, 2030
last updated
Oct 15, 2025
detailed description
Five years after the last study participant is randomized, participants who have received axicabtagene ciloleucel will transition to a separate Long-term Follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments.
official title
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol